A clinical trial is now open for people who have been diagnosed with chronic Hepatitis B Virus (HBV) infection, who have not had treatment for this condition in the last 2 years. Other entry requirements apply.
This clinical trial has been reviewed and approved in accordance with the Australian Human Research Ethics Committee process.
The purpose of this research study is to assess the effectiveness and safety of a novel medicine for the treatment of patients with chronic Hepatitis B. Participating clinics include leading hospitals and medical centres.
The study will assess the effects of the study medicine alone or in combination with other Hepatitis B treatments such as entecavir and pegylated interferon alpha 2a therapy.
Participants will need to agree to participate in the study for approximately 96 weeks, involving 31 clinic visits and a preliminary screening period of up to 60 days.
Travel expenses to clinic appointments will be reimbursed upon presentation of receipts or appropriate documentation.
Participants will need to provide written informed consent to enter into the study. Clinic staff will discuss any other factors that may determine eligibility.
In Australia, about 225,000 people are living with chronic Hepatitis B, which is defined as having had the infection for longer than six months.
It has been estimated that nearly half of those living with chronic Hepatitis B in Australia are not diagnosed.
If you live in South Australia, and are interested to participate, contact the Study Coordinators at the Royal Adelaide Hospital:
Tel: 08 8222 4248